Text Size

Effects of Coenzyme Q10 in PSP and CBD

This study has been completed.
Sponsor:
Information provided by:
Lahey Clinic
ClinicalTrials.gov Identifier:
NCT00532571
First received: September 18, 2007
Last updated: September 19, 2007
Last verified: September 2007
History of Changes
  Purpose

To compare the efficacy, safety and tolerability of Coenzyme Q 10 versus placebo in patients with atypical parkinsonian syndromes corticobasal degeneration (CBD) and progressive supranuclear palsy (PSP) ).


Condition Intervention Phase
Progressive Supranuclear Palsy
Neurological Disorders
 Drug: CoQ10
 Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Effects of Coenzyme Q10 in PSP and CBD, A Randomized, Placebo-Controlled, Double Blind Cross Over Pilot Study

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Lahey Clinic:

Study Start Date: January 2004
Estimated Study Completion Date: September 2005
  Eligibility

Ages Eligible for Study:   40 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients fulfilling the diagnostic criteria of PSP and CBD (above) and who were diagnosed within the past 5 years
  • Age > 40
  • Subjects receiving anticholinergics, amantadine, dopamine agonists, carbidopa/levodopa, eldepryl, or comtan must be on a stable dose for at least 30 days prior to baseline visit.
  • Patients agreeable to participate in the study.

Exclusion Criteria:

  • Prior or concurrent therapy with anticholinergics, amantadine,a dopamine agonist,carbidopa/levodopa or comtan within 30 days of the baseline visit.
  • Parkinsons disease or any other atypical parkinsonism; Parkinsonism due to drugs.
  • History of pallidotomy, thalamotomy, deep brain stimulation or fetal tissue transplant.
  • Previous use of coenzyme Q10 within 60 days of the baseline visit.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00532571

Locations
United States, Massachusetts
Lahey Clinic
Burlington, Massachusetts, United States, 01805
Sponsors and Collaborators
Lahey Clinic
Investigators
Principal Investigator: Diana Apetauerova, MD Lahey Clinic
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00532571     History of Changes
Other Study ID Numbers: CoQ10 with PSP/CBD
Study First Received: September 18, 2007
Last Updated: September 19, 2007
Health Authority: United States: Institutional Review Board

Keywords provided by Lahey Clinic:
CoQ10
PSP
CBD

Additional relevant MeSH terms:
Nervous System Diseases
Supranuclear Palsy, Progressive
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Movement Disorders
Ophthalmoplegia
Ocular Motility Disorders
Cranial Nerve Diseases
Tauopathies
Neurodegenerative Diseases
 Paralysis
Neurologic Manifestations
Eye Diseases
Signs and Symptoms
Coenzyme Q10
Ubiquinone
Micronutrients
Growth Substances
Physiological Effects of Drugs
Pharmacologic Actions
Vitamins

ClinicalTrials.gov processed this record on May 16, 2013